Europe Gastrointestinal Therapeutics Market, 2025-2033
The gastrointestinal therapeutics market in Europe is expected to reach a projected revenue of US$ 14,199.2 million by 2033. A compound annual growth rate of 1.8% is expected of Europe gastrointestinal therapeutics market from 2026 to 2033.
Europe gastrointestinal therapeutics market highlights
The Europe gastrointestinal therapeutics market generated a revenue of USD 12,319.6 million in 2025.
The market is expected to grow at a CAGR of 1.8% from 2026 to 2033.
In terms of segment, branded was the largest revenue generating drug type in 2025.
Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.
Country-wise, UK is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
Market revenue in 2025
USD 12,319.6 million
Market revenue in 2033
USD 14,199.2 million
Growth rate
1.8% (CAGR from 2026 to 2033)
Largest segment
Branded
Fastest growing segment
Generics
Historical data covered
2021 - 2024
Base year for estimation
2025
Forecast period covered
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Branded, Generics
Key market players worldwide
AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares
Other key industry trends
In terms of revenue, Europe region accounted for 28.8% of the global gastrointestinal therapeutics market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 14,565.1 million by 2033.
Europe held the second largest share in the gastrointestinal therapeutics market in 2019. The region is anticipated to experience a steady CAGR over the forecast period, owing to various patent expirations and the subsequent entry of generics in the coming years.
In addition, increasing collaborations between healthcare organizations to enhance awareness and rising availability of varied treatment options can also be attributed to the significant share garnered by the region.
Moreover, regulatory authorities, such as European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA), are consistently working toward ensuring high safety standards for drugs marketed in the region.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gastrointestinal Therapeutics Market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 68.04% in 2025.
Horizon Databook has segmented the Europe gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2021 to 2033.
Europe held the second largest share in the gastrointestinal therapeutics market in 2019. The region is anticipated to experience a steady CAGR over the forecast period, owing to various patent expirations and the subsequent entry of generics in the coming years.
In addition, increasing collaborations between healthcare organizations to enhance awareness and rising availability of varied treatment options can also be attributed to the significant share garnered by the region.
Moreover, regulatory authorities, such as European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA), are consistently working toward ensuring high safety standards for drugs marketed in the region.
Europe Gastrointestinal Therapeutics Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
Branded
Generics
Europe Gastrointestinal Therapeutics Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
Aminosalicylates
Digestive Enzymes
Proton Pump Inhibitors
Laxatives
Anti-emetics
H2 Antagonists
Anti-diarrheals
Biologics/Biosimilar
Other Drug Classes
Europe Gastrointestinal Therapeutics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
Oral
Injectables
Others Route of Administrations
Europe Gastrointestinal Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2033)
Crohn's disease
Ulcerative colitis
GERD
IBS
Others Applications
Europe Gastrointestinal Therapeutics Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Reasons to subscribe to gastrointestinal therapeutics market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of gastrointestinal therapeutics market databook
Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe gastrointestinal therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into Europe gastrointestinal therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Gastrointestinal Therapeutics Market, 2021-2033 (US$M)